Fig. 2
From: Treating non-responders: pitfalls and implications for cancer immunotherapy trial design
The impact of response dichotomy on study efficiency as magnitude of treatment effect (measured by hazard ratio) varies
Fig. 2 | Journal of Hematology & Oncology